U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H31NO3
Molecular Weight 357.4864
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Aroxybutynin

SMILES

CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)C2=CC=CC=C2

InChI

InChIKey=XIQVNETUBQGFHX-QFIPXVFZSA-N
InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H31NO3
Molecular Weight 357.4864
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

PubMed

PubMed

TitleDatePubMed
[Non-coordinated micturition syndrome mimicking posterior urethral valves in a male neonate].
2003 Jul
Acupressure versus oxybutinin in the treatment of enuresis.
2003 Nov-Dec
[Prevalence of urinary incontinence and linked factors in men and women over 65].
2003 Oct 15
Oxybutynin extended-release: a review of its use in the management of overactive bladder.
2004
Drug approval highlights for 2003.
2004 Feb
A population pharmacokinetic model with time-dependent covariates measured with errors.
2004 Jun
Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.
2004 Nov
Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations.
2004 Nov 15
Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder.
2004 Oct
[Urinary incontinence: anticholinergic treatment].
2004 Oct-Dec
A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation.
2005
High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products.
2005 Aug
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices.
2005 Mar 21
Canadian Urological Association guidelines on urinary incontinence.
2006 Jun
New transdermal bioadhesive film containing oxybutynin: In vitro permeation across rabbit ear skin.
2006 Nov 15
Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin.
2006 Oct
Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
2006 Oct
Pharmacologic management of overactive bladder.
2007
Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects.
2007 Jul
Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin.
2007 Jul 13
Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats.
2007 May
Bladder augmentation: Review of the literature and recent advances.
2007 Oct
A review of urodynamic evaluation in children and its role in the management of boys with posterior urethral valves.
2007 Oct
Intravesical treatments for painful bladder syndrome/ interstitial cystitis.
2007 Oct 17
Primary monosymptomatic nocturnal enuresis in children and adolescents.
2007 Sep
Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
2007 Sep
Bladder dysfunction and vesicoureteral reflux.
2008
Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.
2008 Feb 2
Treatment of urinary incontinence after stroke in adults.
2008 Jan 23
The neurogenic bladder: medical treatment.
2008 May
Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor.
2008 May 15
Polymeric matrix membrane sensors for stability-indicating potentiometric determination of oxybutynin hydrochloride and flavoxate hydrochloride urogenital system drugs.
2008 Nov-Dec
Locked-in Syndrome in a Nigerian male with Multiple Sclerosis: a case report and literature review.
2008 Oct 30
Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction.
2009
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study.
2009 Dec 14
Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
2009 Nov
Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease.
2009 Sep
Oxybutynin extended release for the management of overactive bladder: a clinical review.
2009 Sep 21
Application of oxybutynin selective sensors for monitoring the dissolution profile and assay of pharmaceutical dosage forms.
2010
Parasympathetic functions in children with sensory processing disorder.
2010
Medical management of overactive bladder.
2010 Apr
Posterior urethral valves: Morphological normalization of posterior urethra after fulguration is a significant factor in prognosis.
2010 Jul
Liquid Chromatographic Determination of Flavoxate HCl in Pharmaceutical Formulation.
2010 Jul
Quantitative determination of oxybutynin hydrochloride by spectrophotometry, chemometry and HPTLC in presence of its degradation product and additives in different pharmaceutical dosage forms.
2010 Mar 15
[Isolated primary nocturnal enuresis: international evidence based management. Consensus recommendations by French expert group].
2010 May
Anesthetic management of the emergency laparotomy for a patient with multiple sclerosis -A case report-.
2010 Nov
Current practices in treatment of female genital fistula: a cross sectional study.
2010 Nov 10
Urological manifestations of Chikungunya fever: A single centre experience.
2010 Sep
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.
2010 Sep 14
Patents
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:33:23 UTC 2023
Edited
by admin
on Sat Dec 16 19:33:23 UTC 2023
Record UNII
5BRQ29UUB7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Aroxybutynin
INN  
Official Name English
(-)-OXYBUTYNIN
Common Name English
OXYBUTYNIN, (-)-
Common Name English
4-(diethylamino)but-2-yn-1-yl (R)-cyclohexyl(hydroxy)(phenyl)acetate
Systematic Name English
(R)-OXYBUTYNIN
Common Name English
Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, 4-(diethylamino)-2-butyn-1-yl ester, (αR)-
Systematic Name English
aroxybutynin [INN]
Common Name English
R-OXYBUTYNIN
Common Name English
OXYBUTYNIN, (R)-
Common Name English
Code System Code Type Description
FDA UNII
5BRQ29UUB7
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
CAS
119618-21-2
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
SMS_ID
300000045599
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
INN
12152
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
PUBCHEM
6098167
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
NCI_THESAURUS
C190351
Created by admin on Sat Dec 16 19:33:24 UTC 2023 , Edited by admin on Sat Dec 16 19:33:24 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
RACEMATE -> ACTIVE ENANTIOMER
TARGET -> INHIBITOR
ENANTIOMER -> ENANTIOMER
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY